DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1951)

Pulmonary Hypertension | Current Treatment | Detailed, Expanded Analysis (US)

Pulmonary Hypertension | Current Treatment | Detailed, Expanded Analysis (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread, with approved drugs available only for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients. In PAH patients, phosphodiesterase type 5 (PDE-5) inhibitors and endothelin receptor antagonists (ERAs) are most commonly prescribed as first-line treatment, with the more-efficacious prostacyclin therapies used in later lines. Branded therapies dominate the PAH treatment algorithm, and combination therapy is common. Adempas is the only approved therapy for CTEPH patients. PH is a highly lucrative market despite the relatively small patient population.

QUESTIONS ANSWERED

  • What is the current patient share of branded therapies such as United Therapeutics' Orenitram and Remodulin, Actelion’s Opsumit, and Bayer’s Adempas?
  • What effect has the launch of Actelion’s Uptravi had on treatment decisions?
  • What are the anticipated changes in prescribing patterns over the next 12 months?
  • How are specialists utilizing PAH therapies for the treatment of PH WHO Groups 2-5?
  • What are U.S. specialists’ attitudes and perceptions regarding diagnosis and treatment of PH?
  • What are the drivers and constraints determining prescribing practices for PH?

Scope

  • Geography: United States
  • Primary Research: Survey of 101 U.S. cardiologists / pulmonologists
  • Key Drugs Covered: Uptravi, Opsumit, Remodulin, Tyvaso, Orenitram, Adempas, sildenafil, tadalafil, iloprost, epoprostenol

Table of contents

  • Detailed, Expanded Analysis (US)
    • Current Treatment Physician Insights - Pulmonary Hypertension - US - June 2019

Already a Client? Log in to access this report.

  • Pub Date: May 2019
  • Author(s): David Rees, Ph.D
  • David Rees, , is a Business Insights Analyst with the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources Group. Prior to joining Decision Resources Group, Dr. Rees was a Postdoctoral Research Associate at Imperial College London, and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate from the University of Bath.

Purchase Report

Recent reports:
You may also be interested in: